GSK Eyes October FDA Verdict on Chronic Hep B Drug

Why It Matters

A functional cure would break the reliance on lifelong nucleos(t)ide analogues and open a multi‑billion‑dollar market, reshaping the chronic hepatitis B therapeutic landscape.

Key Takeaways

• Bepirovirsen received FDA priority, fast‑track, and breakthrough designations.
• Functional cure rate in B‑WELL trials significantly exceeded placebo.
• Projected peak sales of bepirovirsen are about $2.5 billion annually.
• Current HBV therapies achieve only ~1% functional cure rates.
• HBV causes 56% of liver cancers, 1.1 million deaths yearly.

Pulse Analysis

Chronic hepatitis B remains a global health burden, affecting more than 250 million people and driving over half of liver‑cancer cases. Existing treatments—primarily nucleos(t)ide analogues such as tenofovir—require indefinite use and deliver functional cure rates near 1%, leaving a sizable unmet need for therapies that can sustainably suppress the virus and lower long‑term mortality. The market potential mirrors the earlier hepatitis C boom, which peaked at roughly $10 billion annually, suggesting that a successful HBV cure could unlock comparable revenue streams for innovators.

Bepirovirsen, GSK’s antisense oligonucleotide, targets HBV messenger RNA and pre‑genomic RNA, prompting cellular enzymes to degrade viral transcripts and halt replication. In the B‑WELL 1 and B‑WELL 2 phase‑2 studies, patients receiving bepirovirsen alongside standard care achieved a statistically higher functional cure rate, defined by sustained loss of hepatitis B surface antigen for at least 24 weeks post‑treatment. The drug’s priority, fast‑track, and breakthrough designations have accelerated its FDA review, with a decision slated for October 26, underscoring regulatory confidence in its novel mechanism and clinical promise.

If approved, bepirovirsen could become the first‑in‑class HBV cure, projecting peak sales of about $2.5 billion per year and contributing to GSK’s broader ambition of surpassing $51 million in revenue by 2031. Analysts caution that the HBV market may evolve differently from HCV, given the larger patient pool and the need for long‑term management. Nonetheless, GSK’s pipeline—including gene‑editing ASO candidates and a PAPD5/7 inhibitor—positions the company to capture a substantial share of a market poised for disruption, while offering clinicians a tool to move beyond lifelong therapy toward durable viral control.